GlaxoSmithKline PLC (GSK.L)

GSK.L on London Stock Exchange

1,467.00GBp
30 Jan 2015
Change (% chg)

-25.50p (-1.71%)
Prev Close
1,492.50p
Open
1,490.00p
Day's High
1,493.00p
Day's Low
1,467.00p
Volume
11,242,717
Avg. Vol
8,481,508
52-wk High
1,709.00p
52-wk Low
1,296.50p

GSK.L

Chart for GSK.L

About

GlaxoSmithKline plc (GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. GSK’s principal pharmaceutical products include medicines in... (more)

Overall

Beta: 0.50
Market Cap(Mil.): £71,351.67
Shares Outstanding(Mil.): 4,863.78
Dividend: 19.00
Yield (%): 5.45

Financials

  GSK.L Industry Sector
P/E (TTM): 17.10 39.97 40.64
EPS (TTM): 0.86 -- --
ROI: 16.65 18.85 18.12
ROE: 75.96 19.60 18.97
Search Stocks

EU mergers and takeovers (Jan 28)

BRUSSELS, Jan 28 - The following are mergers under review by the European Commission and a brief guide to the EU merger process:

28 Jan 2015

EU clears plans by drugmakers GSK and Novartis to trade assets

- The European Commission on Wednesday approved a plan by Novartis and GlaxoSmithKline to trade more than $20 billion worth of assets, part of a reshaping of the drug industry at a time of healthcare spending cuts and more competition.

28 Jan 2015

UPDATE 1-EU clears plans by drugmakers GSK and Novartis to trade assets

* Large companies try to focus on leading businesses (Recasts with oncology business, adds details)

28 Jan 2015

BRIEF-EU clears GSK-Novartis three-part deal with conditions

* Received clearance from European Commission of its proposed three-part transaction with Novartis

28 Jan 2015

RPT-EU clears GSK's acquisition of Novartis vaccines with conditions

BRUSSELS, Jan 28 - The European Commission said on Wednesday it had approved drugmaker GlaxoSmithKline's acquisition of Novartis' vaccines business, as well as a consumer healthcare joint venture between the two.

28 Jan 2015

EU clears GSK's acquisition of Novartis vaccines with conditions

BRUSSELS, Jan 28 - The European Commission said on Wednesday it had approved drugmaker GlaxoSmithKline's acquisition of Novartis' vaccines business, as well as a consumer healthcare joint venture between the two.

28 Jan 2015

BRIEF-Ablynx says successfully opposes Domantis patent appeal case

* Ablynx successfully opposes patent appeal case by Domantis (GSK)

22 Jan 2015

MSF slams expensive vaccines, urges GSK and Pfizer to cut prices

LONDON - The international charity Medecins Sans Frontieres urged drugmakers GlaxoSmithKline and Pfizer on Tuesday to slash the price of their pneumococcal vaccines to $5 per child in poor countries.

20 Jan 2015

MSF slams expensive vaccines, urges GSK and Pfizer to cut prices

LONDON, Jan 20 - the international charity Medecins Sans Frontieres urged drugmakers GlaxoSmithKline and Pfizer on Tuesday to slash the price of their pneumococcal vaccines to $5 per child in poor countries.

20 Jan 2015

More unit IPOs an option for evolving GlaxoSmithKline

LONDON - GlaxoSmithKline could consider more partial public share offerings for component units as it evolves in the coming years, potentially pointing to a break-up of the group if this offers value to shareholders.

16 Jan 2015

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Validea
$12.00
Provider: Stock Traders Daily
$20.00
Provider: Sadif Analytics Prime
$10.00
Provider: Sadif Analytics Prime
$10.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks